Tsao David sold $2.5M of BLLN

Tsao David (Chief Technology Officer) sold 20,000 shares of BillionToOne, Inc. (BLLN) at an average of $124.88 ($122.84–$126.90, $2.50M total) across 10 trades on 2026-07-13 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Tsao David
Published Jul 15, 2026, 8:38 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 15, 2026, 8:42 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$BLLN
Neutral
medium confidence
Mentioned
$BLLN
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$BLLNNeutralLow
01

Why it matters

The main tradable element is the disclosed insider selling amount and the fact it was pre-arranged under Rule 10b5-1, which generally reduces interpretive weight.

02

Market read

Traders may monitor for follow-on insider activity, but this specific disclosure is unlikely to drive a major repricing without accompanying fundamental news.

03

What to watch

The filing does not disclose any new company-specific operational or financial information; traders should avoid extrapolating fundamentals from one insider transaction.

Relevance 5/10Novelty 5/10Timing: Filed on 2026-07-15 after the 2026-07-13 insider sale execution.

Background

This is an SEC Form 4 insider transaction by BillionToOne CTO Tsao David, executed across 10 trades on 2026-07-13 and reported on 2026-07-15.

Company-level read

Ticker impact

$BLLNNeutralMedium confidence
Context

BillionToOne CTO Tsao David sold about $2.50M of BLLN shares in an open-market transaction under a 10b5-1 plan.

Expected impact

Likely limited near-term impact; any move would be small and sentiment-driven.

Evidence & confidence

Form 4 shows a pre-arranged 10b5-1 plan and a single insider sale, which typically has less signaling value than discretionary selling.

Market effects

No clear sector read-through from a single 10b5-1 insider sale at one biotech/diagnostics issuer.

None indicated.

None indicated.

Counterpoint

Because the sale is explicitly under a 10b5-1 plan, it may reflect liquidity planning rather than bearish expectations, so the market may ignore it.

Key entities

  • BillionToOne, Inc.

    Company whose insider sale is disclosed on Form 4.

  • Tsao David

    Chief Technology Officer and reporting insider who sold shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

Med

Why is BillionToOne stock sliding today?

BillionToOne stock fell 6.2% in pre-market trading after Fuzzy Panda Research disclosed a short position and alleged regulatory and billing misconduct, including overbilling and potential unlawful practices. The company's stock had already declined from its 52-week high of $150.44, and broader market pressures contributed to the decline.

$BLLNMed

BillionToOne shares slide in pre-market trading following short-seller report

BillionToOne (BLLN) shares fell 6% premarket after a short-seller report alleged improper billing, undisclosed regulatory scrutiny, and clinical claim weaknesses. Fuzzy Panda Research, which holds a short position, cited FOIA records, anonymous sources, and billing data. The report claims potential EBITDA reduction of 80% and False Claims Act penalties up to $1.2B. BillionToOne has not responded.

$BLLNMed

BillionToOne: Q3 Earnings Snapshot

BillionToOne (BLLN) reported Q3 earnings of $17.4M, or 32 cents per share, beating estimates of 16 cents. Revenue was $123M, exceeding forecasts of $116.2M. The company expects full-year revenue between $460M and $470M. Shares have risen 39% YTD.